The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of included studies.

The first author	Date	Disease	Intervene measures		BCVA baseline value		CRT baseline value
			Treatment group	Control group	Treatment group	Control group	Treatment group	Control group
Callanan [6]	2016	DME	On the 1st/5th/10th month, 0.7 mg DEX	PRN after IVR 0.5 mg	60.2 ± 9.74	60.4 ± 9.34	465 ± 136	471 ± 140
Danis [7]	2016	DME	0.7 or 0.35 mg DEX	Sham injection	N/A	N/A	463 ± 156	463.9 ± 132.6
Maturi [8]	2016	DME	0.7 or 0.35 mg DEX and PRN after 6 months	Sham injection	N/A	N/A	469 ± 171	462 ± 152
Ozsaygili [9]	2020	DME	PRN after 0.7 mg DEX	PRN after IVA 2 mg for 3 months	46.3 ± 4.4	47.5 ± 3.1	615.2 ± 150.4	576.5 ± 75.3
Shah [10]	2016	DME	0.7 mg DEX at 1, 3, and 6 months	IVR 1.25 mg for consecutive months	59 ± 13	59 ± 12	485 ± 122	458 ± 100
Sharma [11]	2020	DME	0.7 mg DEX and PRN after 3 months	IVB1.25 mg/IVR 0.5 mg and PRN after 1 month	N/A	N/A	460.95 ± 125.46	443.55 ± 131.53
Gillies [12]	2014	DME	Every four months 0.7 mg DEX and PRN	Every one month IVB 0.5 mg and PRN	55.5 ± 12.5	56.3 ± 11.9	474.3 ± 95.9	503 ± 140.9
Xiaoxin Li [13]	2017	BRVO CRVO	0.7 mg DEX	Sham injection	52.6 ± 10.8	53.1 ± 10.5	683 ± 242	643 ± 213
			0.7 mg DEX	Sham injection
Bandello [14]	2018	BRVO	PRN after 0.7 mg DEX was given in the 1st and 5th month	Continuous 5 months of IVR and PRN	59.2 ± 10.9	547 ± 163	544 ± 168	59.2 ± 10.9
Feltgen [15]	2018	BRVO	0.7 mg DEX and PRN	0.5 mg IVR and PRN	58.3 ± 10.8	56.8 ± 10.0	547.3 ± 178.9	547.3 ± 178.9
		CRVO	0.7 mg DEX and PRN	0.5 mg IVR and PRN	53.2 ± 16.1	54.1 ± 15.8	721.2 ± 231.1	698.8 ± 228.6
Hattenbach [16]	2018	BRVO	0.7 mg DEX and sham injection after two months and PRN	Continuous 3 months of IVR and PRN	N/A	N/A	N/A	N/A
Hoerauf [17]	2016	CRVO	0.7 mg DEX and sham injection after six months	Continuous 3 months of IVR and PRN	51.5 ± 15.6	51.7 ± 16.5	705.2 ± 231.1	723.8 ± 245.9
Kumar [18]	2019	BRVO	0.7 mg DEX	Continuous 3 months of IVR 0.5 mg	0.64 ± 0.15 (6/24)	0.68 ± 0.13 (6/30)	493.67 ± 100.79	487.53 ± 105.90

IVA: intravitreal aflibercept; IVB: intravitreal bevacizumab; IVR: intravitreal ranibizumab.